How the FDA Lied to the American People About Covid-19 'Clinical Trials' | Sasha Latypova

"Vaccines can reach the arms of Americans under investigational or non-investigational pathways that are separate and distinct." —Citizen Petition Regarding Covid-19 Vaccine Licensure https://flashlightsproductions.substack.com/p/how-the-fda-lied-to-the-american?utm_source=youtube This is the second part of my interview with Sasha Latypova in which we discuss the petition's arguments in detail. The petition was filed in December 2025 by Children's Health Defense to request that the FDA revoke the Biologics License Application approvals (BLAs) for the Pfizer and Moderna Covid-19 shots. Latypova wrote extensive parts of the petition. THE PETITION'S CORE LEGAL ARGUMENT Products developed under Emergency Use Authorization (EUA) cannot simply be granted Biologics License Applications (BLAs). It's like declaring sewage to be water. But the FDA retroactively granted Pfizer's and Moderna's mRNA Covid-19 vaccines full BLA approval they never legally earned. Therefore, the citizen petition argues, these products have been misbranded. Misbranding is not a minor infraction, Sasha Latypova told me, but a federal crime that can trigger seizure, injunction, criminal penalties, and license revocation. WHY IS MISBRANDING SUCH A BIG DEAL? It's a long and difficult process to obtain BLA approval from the FDA. Under section 351 of the Public Health Service Act, FDA may approve a BLA only if the vaccine is shown to be safe, pure, and potent for its intended use. In addition, it must be manufactured in facilities that consistently meet regulatory standards. Usually, it takes many years to obtain BLA approval. CHAPTERS 0:00:05 Citizen Petition Overview and Claim of Vaccine Misbranding 0:01:38 FDA's Original Mandate: Misbranding, Adulteration, Interstate Commerce 0:02:35 Federal vs State Authority and Possibility of State‑Level Divergence 0:05:04 Misbranding as a Serious Federal Crime and FDA's Dormant Powers 0:05:36 Investigational vs Non‑Investigational (EUA) Pathways 0:09:02 PREP Act Origins and Congressional Justification for EUA Countermeasures 0:13:08 No True Clinical Trials: EUA Products and "The Trial Charade" 0:14:46 Brooke Jackson's Case 0:22:59 Media Framing: "Technicalities" vs Binding Law on Labeling and Pathways 0:27:39 Core Demands of the Petition: Revoke BLAs, Re‑Designate as EUA Products 0:29:43 Informed Consent, Nuremberg Legacy, and the Missing IRB Oversight 0:32:45 EUA Products Cannot Be Mandated – Yet Mandates Were Imposed Anyway 0:34:53 EUA Suspends FDCA Safeguards: cGMP Deviations and Non‑Regulation 0:39:56 Expiration Date Extensions and the 2069 Pfizer Lot Anomaly 0:48:46 Comparing BLA Standards vs EUA: Safety, Purity, Potency, Sterility, Identity 0:54:31 Manufacturing Process Validation and Extreme Lot‑to‑Lot Variability 1:05:30 Petition's Legal Conclusion on FDA Violations